This subproject represents an estimate of the percentage of the CTSA funding that is being utilized for a broad area of research (AIDS research, pediatric research, or clinical trials). The Total Cost listed is only an estimate of the amount of CTSA infrastructure going towards this area of research, not direct funding provided by the NCRR grant to the subproject or subproject staff. The UCLA CTSI is an academic-clinical-community partnership designed to accelerate scientific discoveries and clinical breakthroughs to improve health in the most populous and diverse county in the United States. An ethnic, economic and cultural mosaic, Los Angeles County provides challenges for health and disease research that few counties replicate. Our mission is to create a borderless clinical and translational research institute that brings UCLA innovations and resources to bear on the greatest health needs of Los Angeles. We are aligning our strengths to support clinical and translational science that is in full partnership with and responsive to the needs of our Los Angeles community. Our UCLA CTSI is bridging disciplinary and institutional boundaries to create transdisciplinary teams focused on the greatest opportunities as well as the greatest needs in our region. CTSA funding will accelerate our progress in achieving our transformative mission and allow the UCLA CTSI to make significant contributions to the goals of the national CTSA consortium. To accomplish our mission the UCLA CTSI has established five goals: 1) Create an academic home for clinical and translational science that integrates and builds on the many strengths of UCLA and its partners, 2) Build transdisciplinary research teams to accelerate and translate discovery to improve health, 3) Transform educational and career development programs to promote the next generation of clinician investigators and translational scientists, 4) Advance and expand strong bi-directional academic-community partnerships to ensure that new scientific discovery is relevant to community needs and, 5) Serve as a national resource for collaborative research through regional, statewide and national CTSA consortia. In transforming our research enterprise, the UCLA-CTSI is guided by core principles including team science, flexible research infrastructure and community engagement. The UCLA CTSI is built on a strong foundation of success in discovery, translational science, community engagement and health services research. Unique resources of the UCLA CTSI include close collaborations with world-leading centers, institutes, schools and programs with which we will co-fund and conduct our clinical and translational science. With institutional support in the pre-award period, the UCLA CTSI has taken significant strides to transform its approach to clinical and translational biomedical research. CTSA funding will accelerate our progress in achieving our transformative mission and allow the UCLA CTSI to make significant contributions to the goals of the national CTSA consortium.

Public Health Relevance

Los Angeles County offers an ideal environment for developing effective translational strategies and faces challenges including subpopulations who are underrepresented in all phases of research. Further its fragmented health care systems require implementation, dissemination and diffusion research for scientific discovery to have a large social impact. As the US population becomes more diverse in the 21^'Century, our experiences and successes will offer a model for health improvement nationwide.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Linked Specialized Center Cooperative Agreement (UL1)
Project #
1UL1RR033176-01
Application #
8365242
Study Section
Special Emphasis Panel (ZRR1-CR-3 (01))
Project Start
2011-06-01
Project End
2012-02-29
Budget Start
2011-06-01
Budget End
2012-02-29
Support Year
1
Fiscal Year
2011
Total Cost
$7,321,847
Indirect Cost
Name
University of California Los Angeles
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Tighiouart, Mourad; Cook-Wiens, Galen; Rogatko, André (2018) A Bayesian adaptive design for cancer phase I trials using a flexible range of doses. J Biopharm Stat 28:562-574
Balakrishnan, Poojitha; Jones, Miranda R; Vaidya, Dhananjay et al. (2018) Ethnic, Geographic, and Genetic Differences in Arsenic Metabolism at Low Arsenic Exposure: A Preliminary Analysis in the Multi-Ethnic Study of Atherosclerosis (MESA). Int J Environ Res Public Health 15:
Moallem, Nathasha R; Courtney, Kelly E; Ray, Lara A (2018) The relationship between impulsivity and methamphetamine use severity in a community sample. Drug Alcohol Depend 187:1-7
Floyd, J S; Sitlani, C M; Avery, C L et al. (2018) Large-scale pharmacogenomic study of sulfonylureas and the QT, JT and QRS intervals: CHARGE Pharmacogenomics Working Group. Pharmacogenomics J 18:127-135
Kulminski, Alexander M; Huang, Jian; Loika, Yury et al. (2018) Strong impact of natural-selection-free heterogeneity in genetics of age-related phenotypes. Aging (Albany NY) 10:492-514
Seyerle, A A; Sitlani, C M; Noordam, R et al. (2018) Pharmacogenomics study of thiazide diuretics and QT interval in multi-ethnic populations: the cohorts for heart and aging research in genomic epidemiology. Pharmacogenomics J 18:215-226
Ray, Lara A; Green, ReJoyce; Roche, Daniel J O et al. (2018) Pharmacogenetic Effects of Naltrexone in Individuals of East Asian Descent: Human Laboratory Findings from a Randomized Trial. Alcohol Clin Exp Res 42:613-623
Jo Hodonsky, Chani; Schurmann, Claudia; Schick, Ursula M et al. (2018) Generalization and fine mapping of red blood cell trait genetic associations to multi-ethnic populations: The PAGE Study. Am J Hematol :
Jimenez, Jose L; Tighiouart, Mourad; Gasparini, Mauro (2018) Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents. Biom J :
Speier, William; Dzubur, Eldin; Zide, Mary et al. (2018) Evaluating utility and compliance in a patient-based eHealth study using continuous-time heart rate and activity trackers. J Am Med Inform Assoc 25:1386-1391

Showing the most recent 10 out of 345 publications